sm08502

Small moleculeexperimental

Clinical trial activity

6 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Nov 6, 2017 (NCT03355066)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCN(c2cc(C(=O)Nc3cc4cc(-c5cnn(C)c5)ccc4cn3)ccn2)CC1
Mol. weight
427.51 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06856499Phase 1Dec 31, 2025National Cancer Institute (NCI), National Institutes of Health (NIH), University of Colorado, Denver
NCT07155200Phase 1/Phase 2 (Phase 2)Dec 31, 2025Biosplice Therapeutics, Washington University in St. Louis
NCT07032285Phase 2Jan 15, 2025Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas, Biosplice Therapeutics
NCT06484062Phase 1Dec 6, 2024Harvard University, National Cancer Institute (NCI)
NCT05084859Phase 1Nov 3, 2021Biosplice Therapeutics
NCT03355066Phase 1Nov 6, 2017Biosplice Therapeutics
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Biosplice TherapeuticsFor profit4222017
National Cancer Institute (NCI)Government2112024
Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasAcademic/Hospital1112025
Harvard UniversityAcademic/Hospital1012024
National Institutes of Health (NIH)Government1012025
University of Colorado, DenverAcademic/Hospital1112025
Washington University in St. LouisAcademic/Hospital1112025
7 organizations
Page 1 / 1